Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. [PDF]
We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for
Yun DH+8 more
europepmc +11 more sources
Audit of Antimanic Agents Monitoring in a High Secure Hospital [PDF]
AimsAntimanic agents are effective in the management of mood disorders and other neuropsychiatric conditions such as epilepsy and aggression. These medications may cause serious side-effects and affect vital organs; hence, specific checks are recommended before initiation and for continuous use of these medications.
Oluwaranti O+3 more
europepmc +4 more sources
Can antipsychotic agents be considered as real anti-manic treatments ? [PDF]
Until now, in various parts of the world, no consensus has been reached with regard to the treatment of acute mania. Controlled clinical trials have at last provided irrefutable evidence for the effectiveness of lithium, which had long been used alone, as well as that of divalproate or its derivatives and, to a lesser extent, carbamazepine (1).
Michel eBourin
doaj +5 more sources
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. [PDF]
Increasing data suggest that impairments of cellular plasticity underlie the pathophysiology of bipolar disorder. In this context, it is noteworthy that AMPA glutamate receptor trafficking regulates synaptic plasticity, effects mediated by signaling cascades, which are targets for antimanic agents.
Du J+7 more
europepmc +7 more sources
This review aimed to clarify whether antimanic agents used in Japan are superior to placebo for the treatment of acute mania, based on reports of randomized controlled trials (RCTs) conducted in Japan and other East Asian countries.
Kanako Ishizuka, Toshiya Inada
doaj +2 more sources
The impact of high-risk medications on mortality risk among older adults with polypharmacy: evidence from the English Longitudinal Study of Ageing [PDF]
Background Polypharmacy is common among older people and is associated with an increased mortality risk. However, little is known about whether the mortality risk is related to specific medications among older adults with polypharmacy.
Yun-Ting Huang+3 more
doaj +5 more sources
Existing and emerging pharmacological approaches to the treatment of mania: A critical overview [PDF]
Manic episodes are a defining, frequent and dramatically disabling occurrence in the course of Bipolar Disorder type I. Current pharmacotherapy of mania lists a good number of agents, but differences in efficacy and safety profiles among these agents ...
Giulio Sparacino+3 more
doaj +2 more sources
Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports. [PDF]
ABSTRACT Data addressing safety concerns related to potential drug interactions between cannabis‐derived products and pharmaceutical medications in the pediatric population are lacking. In this study, we retrieved case reports through a published literature search using PubMed and spontaneous reporting data using the Food and Drug Administration's ...
Chapin MR+7 more
europepmc +2 more sources
Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran [PDF]
Naghmeh Mokhber1, Carol J Lane2, Mohamad R Azarpazhooh3, Elham Salari4, Reza Fayazi5, Mohamad T Shakeri6, Allan H Young71Assistant Professor of Psychiatry, 3Assistant Professor of Neurology, 4Mashhad Department of Forensic Psychiatry, 5Assistant ...
Naghmeh Mokhber+5 more
doaj +3 more sources
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug ...
Pavel Mohr+4 more
doaj +1 more source